Smith & Nephew SNATS (NYSE:SNN) Hits New 1-Year Low – Time to Sell?

Smith & Nephew SNATS, Inc. (NYSE:SNN)’s stock price hit a new 52-week low on Thursday. The stock traded as low as $26.38 and last traded at $26.4550, with a volume of 588841 shares traded. The stock had previously closed at $26.96.

Wall Street Analyst Weigh In

Several analysts have commented on SNN shares. BTIG Research initiated coverage on shares of Smith & Nephew SNATS in a research note on Monday, August 31st. They set a “neutral” rating for the company. Morgan Stanley cut shares of Smith & Nephew SNATS from an “overweight” rating to an “equal weight” rating in a report on Wednesday, September 2nd. Barclays downgraded shares of Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a research report on Wednesday, August 5th. Zacks Research raised shares of Smith & Nephew SNATS from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 8th. Finally, Bank of America downgraded Smith & Nephew SNATS from a “buy” rating to a “neutral” rating in a research report on Tuesday, September 8th. One investment analyst has rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $31.91.

Smith & Nephew SNATS Stock Performance

The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 2.14. The firm’s 50 day moving average price is $29.14 and its 200-day moving average price is $30.42.

Smith & Nephew SNATS Dividend Announcement

The firm also recently declared a dividend, which will be paid on Friday, November 6th. Shareholders of record on Friday, October 2nd will be given a dividend of $0.3120 per share. The ex-dividend date is Friday, October 2nd. This represents a yield of 205.0%.

Institutional Trading of Smith & Nephew SNATS

Institutional investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in Smith & Nephew SNATS during the 2nd quarter worth approximately $505,323,000. River Road Asset Management LLC increased its position in shares of Smith & Nephew SNATS by 13.8% during the fourth quarter. River Road Asset Management LLC now owns 3,169,644 shares of the medical equipment provider’s stock worth $103,996,000 after purchasing an additional 384,926 shares in the last quarter. Bank of America Corp DE purchased a new stake in shares of Smith & Nephew SNATS during the second quarter worth approximately $97,223,000. Bank of New York Mellon Corp acquired a new position in Smith & Nephew SNATS in the 2nd quarter valued at $89,325,000. Finally, Dimensional Fund Advisors LP raised its stake in Smith & Nephew SNATS by 44.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,052,747 shares of the medical equipment provider’s stock valued at $33,436,000 after purchasing an additional 324,080 shares during the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company headquartered in Watford, England. Founded in 1856 by pharmacist Thomas James Smith in Hull, the company has grown from a pharmacy business into a provider of surgical and wound-care products for healthcare professionals and patients.

The company operates through three principal areas: Orthopaedics, Sports Medicine, and Advanced Wound Management. Its products include joint-replacement systems, trauma and extremity devices, arthroscopy equipment, surgical repair technologies, wound dressings, negative-pressure wound therapy systems, and other products used to support healing and tissue recovery.

Smith & Nephew serves hospitals, clinics, surgeons, and patients in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific, and other international regions.